NuCana Dirección
Dirección controles de criterios 3/4
El CEO de NuCana's es Hugh Griffith , nombrado en Mar 2008, tiene una permanencia de 16.08 años. compensación anual total es £974.59K, compuesta por 58.9% salario y 41.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.42% de las acciones de la empresa, por valor de $201.90K. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 5.9 años, respectivamente.
Información clave
Hugh Griffith
Chief Executive Officer (CEO)
UK£974.6k
Compensación total
| Porcentaje del salario del CEO | 58.9% |
| Permanencia del CEO | 16.1yrs |
| Participación del CEO | 2.4% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14
We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
Oct 15Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation
Jul 01Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Mar 15Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Nov 30NuCana: An Intriguing 'Sum Of The Parts' Story
Sep 22NuCana GAAP EPS of -£0.07
Aug 17NuCana regains Nasdaq compliance
Jul 27NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
Jul 13Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
May 02We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Jan 17NuCana: Preparing For A Critical 2022
Dec 08We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow
Sep 30NuCana: The Market Continues To Overlook Its ProTide Platform Technology
Sep 11We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth
Jun 01Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth
Feb 15How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?
Dec 22
NuCana (NCNA) Investor Presentation - Slideshow
Dec 02NuCana reports Q3 results
Nov 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | UK£975k | UK£574k | -UK£28m |
| Sep 30 2023 | n/a | n/a | -UK£35m |
| Jun 30 2023 | n/a | n/a | -UK£33m |
| Mar 31 2023 | n/a | n/a | -UK£31m |
| Dec 31 2022 | UK£1m | UK£552k | -UK£32m |
| Sep 30 2022 | n/a | n/a | -UK£30m |
| Jun 30 2022 | n/a | n/a | -UK£34m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£907k | UK£531k | -UK£41m |
| Sep 30 2021 | n/a | n/a | -UK£39m |
| Jun 30 2021 | n/a | n/a | -UK£40m |
| Mar 31 2021 | n/a | n/a | -UK£36m |
| Dec 31 2020 | UK£920k | UK£551k | -UK£31m |
| Sep 30 2020 | n/a | n/a | -UK£26m |
| Jun 30 2020 | n/a | n/a | -UK£22m |
| Mar 31 2020 | n/a | n/a | -UK£20m |
| Dec 31 2019 | UK£828k | UK£498k | -UK£21m |
| Sep 30 2019 | n/a | n/a | -UK£17m |
| Jun 30 2019 | n/a | n/a | -UK£16m |
| Mar 31 2019 | n/a | n/a | -UK£13m |
| Dec 31 2018 | UK£786k | UK£467k | -UK£14m |
| Sep 30 2018 | n/a | n/a | -UK£15m |
| Jun 30 2018 | n/a | n/a | -UK£26m |
| Mar 31 2018 | n/a | n/a | -UK£28m |
| Dec 31 2017 | UK£635k | UK£330k | -UK£23m |
Compensación vs. Mercado: La compensación total de Hugh($USD1.20M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).
Compensación vs. Ingresos: La compensación de Hugh ha sido consistente con los resultados de la empresa en el último año.
CEO
Hugh Griffith (55 yo)
16.1yrs
Permanencia
UK£974,586
Compensación
Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 16.1yrs | UK£974.59k | 2.42% £ 202.4k | |
| Chief Financial Officer | 8.5yrs | sin datos | 0.30% £ 24.8k | |
| Head of Translational Medicine | 6.3yrs | sin datos | 0% £ 0 | |
| Chief Medical Officer | 2.7yrs | sin datos | 0.00019% £ 15.9 | |
| Senior Vice President of Clinical Operations | 4.3yrs | sin datos | sin datos | |
| Senior Vice President of Medical & Clinical Development | 3.5yrs | sin datos | sin datos | |
| Company Secretary | no data | sin datos | sin datos |
5.3yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de NCNA es experimentado (5.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 16.1yrs | UK£974.59k | 2.42% £ 202.4k | |
| Independent Non-Executive Chairman | 3.3yrs | UK£78.77k | 0% £ 0 | |
| Independent Non-Executive Director | 14.3yrs | UK£47.85k | 0.053% £ 4.5k | |
| Independent Non Executive Director | 6yrs | UK£56.56k | 0% £ 0 | |
| Independent Non-Executive Director | 3.6yrs | UK£29.25k | 0.0010% £ 88.0 | |
| Independent Director | 2.4yrs | UK£54.23k | 0.0090% £ 752.3 | |
| Independent Non Executive Director | 5.9yrs | UK£65.08k | 0% £ 0 |
5.9yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de NCNA se considera experimentada (5.9 años de antigüedad promedio).